Sachin Vadgama

6PUBLICATIONS
26CO-AUTHORS
Time-series analysisEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Feb 18, 2026
Time to access matters: patient gains from faster CAR T-cell reimbursement in Europe.

Yan Zhi Tan, Emily Breislin, Matthew Woods

|Aug 07, 2025
Evaluating the Role and Policy Implications of Using External Evidence in Survival Extrapolations: A Case Study of Axicabtagene Ciloleucel Therapy for Second-Line DLBCL.

Sam Harper, Daniela Afonso, Karina Watts

|May 16, 2025
Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis.

Andrea P Chung, Jason T Shafrin, Sachin Vadgama

|Aug 10, 2024
The Health Impacts of Better Access to Axicabtagene Ciloleucel: The Case of Spain.

Raúl Córdoba, Lucía López-Corral, María Presa

|Apr 25, 2024
"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes.

Sachin Vadgama, Marcelo C Pasquini, Richard T Maziarz

|Sep 19, 2023
Axicabtagene ciloleucel compared to standard of care in Swedish patients with large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial.

Anne Sofie Ledgaard Loftager, Anne Danø, Oskar Eklund

Pageof 1

Frequent Collaborators

2 joint publications

Oskar Eklund

2 joint publications

Richard T Maziarz

2 joint publications

Brett Doble

1 joint publications

Anne Sofie Ledgaard Loftager